Compensation for Onglyza/Kombiglyze (saxagliptin) Who Suffered Heart Failure, Congestive Heart Failure, Cardiac Failure
Patients taking the incretin mimetic Type 2 diabetes drugs like Onglyza or Kombiglyze (saxagliptin) face an increased risk of devastating and potentially life-threatening side effects, like congestive heart failure, heart attack, pancreatitis, pancreatic cancer, heart failure and wrongful death. If you believe you or a loved one has been adversely affected by side effects of Onglyza and Kombiglyze, contact a knowledgeable product liability lawyer as soon as possible to discuss your legal options. You may have grounds to file an Onglyza or Kombiglyze injury lawsuit against AstraZeneca and Bristol-Myers Squibb, in order to pursue the financial compensation you and your loved ones deserve for your injuries, medical expenses, pain and suffering, and other related damages.
Allegations regarding Onglyza/Kombiglyze (saxagliptin)
Allegations in complaints against this group of drugs and their makers include:
- Onglyza is a defective drug and poses an unreasonable risk of side effects and particularly congestive heart failure, heart failure and cardiac failure many of which turn out to be terminal.
- AstraZeneca and Bristol-Myers Squibb failed to adequately research the safety and effectiveness of Onglyza.
- The manufacturers knew or should have known about the potential for Onglyza to cause pancreatitis and other complications.
- AstraZeneca and Bristol-Myers Squibb concealed the risks of Onglyza from consumers and the medical community. These omissions prevented individuals from making fully informed decisions regarding their health.
Studies linking Onglyza/Kombiglyze (saxagliptin) to Serious Injuries
"Unfortunately, when drug manufacturing companies conceal these drug risks from the public, consumers are robbed of their right to make educated decisions about which medications are safe for them to use, and which aren’t"
Studies linking Onglyza/Kombiglyze (saxagliptin) to Serious Injuries
One deadly side effect linked to Onglyza treatment is heart failure, a serious condition occurring when the heart fails to pump blood adequately. According to an April 2015 study published in the New England Journal of Medicine, patients treated with Onglyza and other incretin mimetic diabetes drugs faced a 27% increased risk of hospitalization for heart failure complications. That same month, an FDA analysis of clinical trial data indicated that patients treated with Onglyza may have a significantly increased risk of heart failure and death.
Information about the alleged link between Onglyza and serious side effects in diabetes patients is not new. In November 2011, a warning about the alleged risk of pancreatitis complications was added to the Onglyza drug label, highlighting the potential for severe inflammation of the pancreas to lead to hospitalization, pancreatic cancer and death.
In 2013, a study published in medical journal Diabetes found a link between DPP-4 inhibitor drugs like Onglyza and the presence of abnormal pre-cancerous cells in the pancreas, and that same year, the FDA issued a safety alert indicating that the agency would be investigating “unpublished new findings […] that suggest an increased risk of pancreatitis and pre-cancerous cellular changes […] in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.”
Did you or a loved one suffer Congestive Heart Failure, Heart Failure or Cardiac Failure while taking Type 2 Diabetes Drugs Onglyza or Kombiglyze (saxagliptin) ?
Find out if you may qualify for compensation.
Find Out MoreConsumer Safety Watch offers safety advocate services and attorney referral services for patients throughout the United States including the states of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin and Wyoming.
Consumer Safety Watch offers consumer safety advocate services or can help you find an attorney throughout the United States including the following cities: Albuquerque, NM; Arlington, TX; Atlanta, GA; Austin, TX; Baltimore, MD; Boston, MA; Charlotte, NC; Chicago, IL; Cleveland, OH; Colorado Springs, CO; Columbus, OH; Dallas, TX; Denver, CO; Detroit, MI; Fresno, CA; Fort Worth, TX; Indianapolis, IN; Honolulu, HI; Houston, TX; Jacksonville, FL; Kansas City, KS; Kansas City, MO; Las Vegas, NV; Long Beach, CA; Los Angeles, CA; Louisville, KY; Memphis, TN; Mesa, AZ; Miami, FL; Miami, OH; Milwaukee, WI; Minneapolis, MN; Nashville, TN; New York City, NY; Oakland, CA; Oklahoma City, OK; Omaha, NE; Philadelphia, PA; Phoenix, AZ; Pittsburgh, PA; Portland, OR; Sacramento, CA; San Antonio, Tx; San Diego, CA; San Francisco, CA; San Jose, CA; Seattle, WA; St. Louis, MO; Tampa, FL; Tucson, AZ; Tulsa, Virginia Beach, VA; Washington, DC; Wichita, KS.
This website is not affiliated with any pharmaceutical or medical device company or any trademarked product. Results are not guaranteed. This website provides a free matching service and is not responsible for information or services from third party providers. Consumer Safety Watch is not a law firm. Every case is different and services available can vary.